/
Neurology
Neuropathy
66
Pipeline Programs↗
130
Active Trials↗
84
Companies Involved↗
Neuropathy is a moderately active landscape with 66 programs across 84 companies. The most active players are Argenx, Dianthus Therapeutics, GSK. 13 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical30
Phase 17
Phase 216
Phase 313
Approved
No programs
Analysis
Modality Breakdown
86%
Small molecule
48 of 56 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 56 classified programs, each share of the total. Modality classified for 91% of 66 pipeline programs.
Analysis
Trial Status
540
clinical trials
Completed275 · 51%
Unknown status66 · 12%
Recruiting62 · 11%
Terminated48 · 9%
Not yet recruiting36 · 7%
Active, not recruiting29 · 5%
Other24 · 4%
Clinical Trials
Trial Activity
540 trials
Randomized, Multicenter, Vehicle-Controlled, Double-Masked Phase 3 Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Recruiting·—·Phase 3·NCT07453888·272 enrolled
Page 1 of 36
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)